Robert Cyran, U.S. tech columnist, joined Breakingviews in London in 2003 and moved four years later to New York, where he continues to cover global technology, pharmaceuticals and special situations. Robert began his career at Forbes magazine, where he assisted in the startup of the international version of the magazine. Before working at Breakingviews he worked as a market researcher and reporter covering the pharmaceutical industry. Robert has a Masters degree in economics from Birmingham University and an undergraduate degree from George Washington University.
The idea of the iPhone maker shifting 30% of production elsewhere may concentrate minds as the U.S. and China square up in trade talks. Such a move would take years. Detroit and London show economic clusters rarely implode. But they can erode, and the process is hard to stop.
Array BioPharma has developed several potential blockbusters for others. But it wouldn’t be selling to Pfizer at a 62% premium without an earlier gift from antitrust regulators. A pact between two rivals sent valuable drugs Array’s way, along with cash, making it a juicy target.
The $105 billion chipmaker’s woes extend far beyond the U.S. ban on exports to China’s Huawei. Broadcom’s rapid expansion has made it a supplier to everybody from mobile phone firms to telcos to the auto industry. When their demand for chips declines, growth often slows too.